Biogen says FDA extending review of hemophilia drug

(Reuters) - Biogen Idec Inc on Monday said the U.S. Food and Drug Administration will extend by three months its deadline for reviewing the company's experimental long-acting medicine for hemophilia.

via Reuters: Health News Read More Here..